U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Lung Non-Squamous Non-Small Cell Carcinoma

MedGen UID:
1660179
•Concept ID:
C4324656
•
Neoplastic Process
Synonym: Non-Squamous Non-Small Cell Lung Carcinoma

Definition

A non-small cell lung carcinoma without evidence of squamous differentiation. [from NCI]

Professional guidelines

PubMed

Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up.
Finall A, Davies G, Jones T, Emlyn G, Huey P, Mullard A
J Clin Pathol 2023 Jun;76(6):391-399. Epub 2022 Jan 18 doi: 10.1136/jclinpath-2021-207987. PMID: 35042754

Recent clinical studies

Etiology

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Özgüroğlu M, Kilickap S, Sezer A, Gümüş M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Ho GF, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, He X, Kaul M, Okoye E, Li Y, Li S, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P
Lancet Oncol 2023 Sep;24(9):989-1001. Epub 2023 Aug 14 doi: 10.1016/S1470-2045(23)00329-7. PMID: 37591293
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, Yu Y, Yao W, Chang J, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Wang J, Li P, Qin M, Lu D, Yang J
Lancet Oncol 2022 Feb;23(2):220-233. Epub 2022 Jan 14 doi: 10.1016/S1470-2045(21)00650-1. PMID: 35038432
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F
Lancet Oncol 2019 Jul;20(7):924-937. Epub 2019 May 20 doi: 10.1016/S1470-2045(19)30167-6. PMID: 31122901
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR; OAK Study Group
Lancet 2017 Jan 21;389(10066):255-265. Epub 2016 Dec 13 doi: 10.1016/S0140-6736(16)32517-X. PMID: 27979383Free PMC Article
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators
Lancet Oncol 2016 Nov;17(11):1497-1508. Epub 2016 Oct 10 doi: 10.1016/S1470-2045(16)30498-3. PMID: 27745820Free PMC Article

Diagnosis

Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe.
Hofman P, Calabrese F, Kern I, Adam J, Alarcão A, Alborelli I, Anton NT, Arndt A, Avdalyan A, Barberis M, Bégueret H, Bisig B, Blons H, Boström P, Brcic L, Bubanovic G, Buisson A, Caliò A, Cannone M, Carvalho L, Caumont C, Cayre A, Chalabreysse L, Chenard MP, Conde E, Copin MC, Côté JF, D'Haene N, Dai HY, de Leval L, Delongova P, Denčić-Fekete M, Fabre A, Ferenc F, Forest F, de Fraipont F, Garcia-Martos M, Gauchotte G, Geraghty R, Guerin E, Guerrero D, Hernandez S, Hurník P, Jean-Jacques B, Kashofer K, Kazdal D, Lantuejoul S, Leonce C, Lupo A, Malapelle U, Matej R, Merlin JL, Mertz KD, Morel A, Mutka A, Normanno N, Ovidiu P, Panizo A, Papotti MG, Parobkova E, Pasello G, Pauwels P, Pelosi G, Penault-Llorca F, Picot T, Piton N, Pittaro A, Planchard G, Poté N, Radonic T, Rapa I, Rappa A, Roma C, Rot M, Sabourin JC, Salmon I, Prince SS, Scarpa A, Schuuring E, Serre I, Siozopoulou V, Sizaret D, Smojver-Ježek S, Solassol J, Steinestel K, Stojšić J, Syrykh C, Timofeev S, Troncone G, Uguen A, Valmary-Degano S, Vigier A, Volante M, Wahl SGF, Stenzinger A, Ilié M
ESMO Open 2023 Oct;8(5):101628. Epub 2023 Sep 14 doi: 10.1016/j.esmoop.2023.101628. PMID: 37713929Free PMC Article
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer.
Fujimoto D, Miura S, Tomii K, Sumikawa H, Yoshimura K, Wakuda K, Oya Y, Yokoyama T, Kijima T, Asao T, Tamiya M, Nakamura A, Yoshioka H, Tokito T, Murakami S, Tamiya A, Yokouchi H, Watanabe S, Yamaguchi O, Morinaga R, Jodai T, Ito K, Shiraishi Y, Kogure Y, Shibaki R, Yamamoto N
Sci Rep 2023 Mar 6;13(1):3698. doi: 10.1038/s41598-023-30676-y. PMID: 36878936Free PMC Article
Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications.
Kazdal D, Hofman V, Christopoulos P, Ilié M, Stenzinger A, Hofman P
Genes Chromosomes Cancer 2022 May;61(5):244-260. Epub 2022 Jan 22 doi: 10.1002/gcc.23022. PMID: 34997651
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, Bahce I, Niemeijer ALN, Chang JY, de Groot PM, Nguyen QN, Comeaux NI, Simon GR, Skoulidis F, Lin SH, He K, Patel R, Heymach J, Baas P, Welsh JW
Lancet Respir Med 2021 May;9(5):467-475. Epub 2020 Oct 20 doi: 10.1016/S2213-2600(20)30391-X. PMID: 33096027
Targeting HER2 expression in cancer: New drugs and new indications.
Vranić S, Bešlija S, Gatalica Z
Bosn J Basic Med Sci 2021 Feb 1;21(1):1-4. doi: 10.17305/bjbms.2020.4908. PMID: 32530388Free PMC Article

Therapy

Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.
Awad MM, Govindan R, Balogh KN, Spigel DR, Garon EB, Bushway ME, Poran A, Sheen JH, Kohler V, Esaulova E, Srouji J, Ramesh S, Vyasamneni R, Karki B, Sciuto TE, Sethi H, Dong JZ, Moles MA, Manson K, Rooney MS, Khondker ZS, DeMario M, Gaynor RB, Srinivasan L
Cancer Cell 2022 Sep 12;40(9):1010-1026.e11. Epub 2022 Aug 25 doi: 10.1016/j.ccell.2022.08.003. PMID: 36027916
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Gessner C, Moreno-Jaime B, Passalacqua R, Li S, McGuire K, Kaul M, Paccaly A, Quek RGW, Gao B, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Gullo G, Rietschel P
Nat Med 2022 Nov;28(11):2374-2380. Epub 2022 Aug 25 doi: 10.1038/s41591-022-01977-y. PMID: 36008722Free PMC Article
Targeting HER2 expression in cancer: New drugs and new indications.
Vranić S, Bešlija S, Gatalica Z
Bosn J Basic Med Sci 2021 Feb 1;21(1):1-4. doi: 10.17305/bjbms.2020.4908. PMID: 32530388Free PMC Article
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F
Lancet Oncol 2019 Jul;20(7):924-937. Epub 2019 May 20 doi: 10.1016/S1470-2045(19)30167-6. PMID: 31122901
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR; OAK Study Group
Lancet 2017 Jan 21;389(10066):255-265. Epub 2016 Dec 13 doi: 10.1016/S0140-6736(16)32517-X. PMID: 27979383Free PMC Article

Prognosis

KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
Lim TKH, Skoulidis F, Kerr KM, Ahn MJ, Kapp JR, Soares FA, Yatabe Y
Lung Cancer 2023 Oct;184:107293. Epub 2023 Jul 13 doi: 10.1016/j.lungcan.2023.107293. PMID: 37683526
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Özgüroğlu M, Kilickap S, Sezer A, Gümüş M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Ho GF, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, He X, Kaul M, Okoye E, Li Y, Li S, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P
Lancet Oncol 2023 Sep;24(9):989-1001. Epub 2023 Aug 14 doi: 10.1016/S1470-2045(23)00329-7. PMID: 37591293
Targeting HER2 expression in cancer: New drugs and new indications.
Vranić S, Bešlija S, Gatalica Z
Bosn J Basic Med Sci 2021 Feb 1;21(1):1-4. doi: 10.17305/bjbms.2020.4908. PMID: 32530388Free PMC Article
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F
Ann Oncol 2020 Nov;31(11):1491-1505. Epub 2020 Aug 24 doi: 10.1016/j.annonc.2020.07.014. PMID: 32853681
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M
Lancet 2014 Aug 23;384(9944):665-73. Epub 2014 Jun 2 doi: 10.1016/S0140-6736(14)60845-X. PMID: 24933332

Clinical prediction guides

KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
Lim TKH, Skoulidis F, Kerr KM, Ahn MJ, Kapp JR, Soares FA, Yatabe Y
Lung Cancer 2023 Oct;184:107293. Epub 2023 Jul 13 doi: 10.1016/j.lungcan.2023.107293. PMID: 37683526
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.
Awad MM, Govindan R, Balogh KN, Spigel DR, Garon EB, Bushway ME, Poran A, Sheen JH, Kohler V, Esaulova E, Srouji J, Ramesh S, Vyasamneni R, Karki B, Sciuto TE, Sethi H, Dong JZ, Moles MA, Manson K, Rooney MS, Khondker ZS, DeMario M, Gaynor RB, Srinivasan L
Cancer Cell 2022 Sep 12;40(9):1010-1026.e11. Epub 2022 Aug 25 doi: 10.1016/j.ccell.2022.08.003. PMID: 36027916
Targeting HER2 expression in cancer: New drugs and new indications.
Vranić S, Bešlija S, Gatalica Z
Bosn J Basic Med Sci 2021 Feb 1;21(1):1-4. doi: 10.17305/bjbms.2020.4908. PMID: 32530388Free PMC Article
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F
Ann Oncol 2020 Nov;31(11):1491-1505. Epub 2020 Aug 24 doi: 10.1016/j.annonc.2020.07.014. PMID: 32853681
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators
Lancet 2019 May 4;393(10183):1819-1830. Epub 2019 Apr 4 doi: 10.1016/S0140-6736(18)32409-7. PMID: 30955977

Recent systematic reviews

The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials.
Daei Sorkhabi A, ZareDini M, Fazlollahi A, Sarkesh A, Naseri A, Mousavi SE, Nejadghaderi SA, Sullman MJM, Kolahi AA, Safiri S
BMC Pulm Med 2023 Dec 8;23(1):495. doi: 10.1186/s12890-023-02755-3. PMID: 38066549Free PMC Article
EGFR Mutation in Non-squamous Non-small-cell Lung Carcinoma (NS-NSCLC) in the Arab World: A systematic Review.
Nassar D, Chidiac C, Ibrahim E, Abou Zeid K, Haddad F, Kourie H
Gulf J Oncolog 2023 Jan;1(41):54-61. PMID: 36804159
Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.
O'Byrne K, Popoff E, Badin F, Lee A, Yuan Y, Lozano-Ortega G, Eccles LJ, Varol N, Waser N, Penrod JR, Goring S
Lung Cancer 2023 Mar;177:11-20. Epub 2023 Jan 11 doi: 10.1016/j.lungcan.2023.01.006. PMID: 36669321
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.
Siciliano MA, Caridà G, Ciliberto D, d'Apolito M, Pelaia C, Caracciolo D, Riillo C, Correale P, Galvano A, Russo A, Barbieri V, Tassone P, Tagliaferri P
ESMO Open 2022 Jun;7(3):100465. Epub 2022 Apr 12 doi: 10.1016/j.esmoop.2022.100465. PMID: 35427835Free PMC Article
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U, Tsourti Z, Vervita K, Peters S
Lung Cancer 2019 Aug;134:127-140. Epub 2019 May 30 doi: 10.1016/j.lungcan.2019.05.029. PMID: 31319971

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...